Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region
Sponsor: Biomedical Advanced Research and Development Authority
A PHASE1 clinical study on Zika Virus, this trial is completed. The trial is conducted by Biomedical Advanced Research and Development Authority and has accumulated 11 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2019 — Jan 2020 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
May 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting PHASE1
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biomedical Advanced Research and Development Authority
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .